Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
06 December 2022 - 12:07AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December, 2022
Commission File Number: 001-36815
Ascendis Pharma A/S
(Exact Name of Registrant as Specified in Its
Charter)
Tuborg Boulevard 12
DK-2900
Hellerup
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted
by Regulation S-T Rule
101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted
by Regulation S-T Rule
101(b)(7): ☐
INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be
incorporated by reference into the registration statements on
Form S-8 (Registration
Numbers 333-228576,
333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-254101 and 333-261550) and Form F-3 (Registration Numbers
333-209336, 333-211511, 333-216882, 333-223134,333-225284 and
333-256571) of Ascendis
Pharma A/S (the “Company”) (including any prospectuses forming a
part of such registration statements) and to be a part thereof from
the date on which this report is filed, to the extent not
superseded by documents or reports subsequently filed or
furnished.
On December 5, 2022, the Company announced that the U.S.
Food & Drug Administration has allowed the Company to
initiate an expanded access program for its investigational
parathyroid hormone replacement therapy, TransCon PTH
(palopegteriparatide), for adult patients with
hypoparathyroidism.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
Ascendis Pharma A/S |
|
|
|
|
Date: December 5, 2022 |
|
|
|
By: |
|
/s/ Michael Wolff Jensen
|
|
|
|
|
|
|
Michael Wolff Jensen |
|
|
|
|
|
|
Senior Vice President, Chief Legal Officer |
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Feb 2023 to Mar 2023
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Mar 2022 to Mar 2023